The Experimental and Computational Genomics Core (ECGC) is a newly created Core that integrates all of the cancer genomics services in the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The primary mission of the Core is to allow SKCCC investigators to harness the ongoing revolution in cancer genomics to accelerate their basic discovery and translational research. The ECGC has streamlined services that were previously offered through three separate Cores: the Microarray Core, Next-Generation Sequencing Core and Bioinformatics Core. The new joint structure recognizes that the activities of the previous three Cores are highly interdependent and formalizes a long-standing commitment to coordinate computing resources, hiring and educational activities for the common good of the SKCCC. The newly created centralized structure has streamlined access to experimental and computational genomics technologies and expertise, and enhanced opportunities for didactic and hands-on education in both the experimental and computational aspects of cancer genomics. The immense laboratory and analytical expertise brought together in the newly integrated cross-disciplinary Core are now available, in a single and clearly defined Core, to all SKCCC investigators. The services provided by this Core are not available elsewhere. An SKCCC member looking to outside resources would need to independently talk with multiple vendors and would only be able to obtain piecemeal services. This Core is led by Leslie Cope, Ph.D.; Sarah Wheelan, M.D., Ph.D.; and Srinavasan Yegnasubramanian, M.D., Ph.D., who bring together multidisciplinary expertise in genomics technologies, computational biology and biostatistics/bioinformatics. The Core provides access to, and education in, state-of-the-art, next- generation sequencing, microarray technologies and analytical workflows for probing genomic alterations (including SNVs, indels and structural alterations), cancer epigenomics (e.g., ChIP-seq and DNA methylome), transcriptomics and metagenomics. For each project, the Core uses a multidisciplinary clinic model to establish and execute an experimental and analytical plan, first meeting with each investigator and then helping them through all aspects of their genomics experiments, including experimental design, high-throughput microarray or next-generation sequencing workflows, and computational/bioinformatics data analysis. Additionally, the Core provides extensive educational resources, including short courses, workshops and a symposium, so that investigators can gain the skills they need to fully understand and utilize the data and analyses generated. The success of this Core is evidenced by the high level of usage across nearly all Programs and the cited support in a large number of impactful publications, national/international conference abstracts and successful grant applications. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006973-55S2
Application #
9734247
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Bharti, Santosh K; Mironchik, Yelena; Wildes, Flonne et al. (2018) Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft. Oncotarget 9:15326-15339
Jackson, Sadhana; Weingart, Jon; Nduom, Edjah K et al. (2018) The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids Barriers CNS 15:2
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Gorin, Michael A; Rowe, Steven P; Patel, Hiten D et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. J Urol 199:126-132
Jiang, Wei; Zhou, Xiaoyan; Li, Zengxia et al. (2018) Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin. Blood 131:1325-1336
Nagai, Kozo; Hou, Lihong; Li, Li et al. (2018) Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 9:32885-32899
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Baena-Del Valle, Javier A; Zheng, Qizhi; Esopi, David M et al. (2018) MYC drives overexpression of telomerase RNA (hTR/TERC) in prostate cancer. J Pathol 244:11-24
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:

Showing the most recent 10 out of 2393 publications